Akeso details ivonescimab's survival win in biliary tract cancer, a China-only trial
- Akeso presented HARMONi-GI1 at ESMO 2026: its PD-1xVEGF bispecific ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line advanced biliary tract cancer.
- The 682-patient study ran in China only and was sponsored and analyzed by Akeso; overall survival was the key result.
- Summit Therapeutics holds rights outside China, and the data are already prompting Keytruda comparisons.
💡 Points
An overall-survival win over an anti-PD-1/L1 backbone is the claim PD-1xVEGF bispecifics need, and biliary cancer is a small, low-risk place to show it. But a China-only, Akeso-run trial will not settle Western regulators, so the value to Summit hinges on global trials such as its lung program, not on this readout.
#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons ↗